Nanotechnology Based Intranasal Vaccine for COVID-19
TS-062232 — The Need
The current demand in the market is for a safe and effective SARS-CoV-2 vaccine that can induce both antibody and T cell responses. The traditional understanding of antibody-based immunity is incomplete, as virus-infected cells are eliminated with the help of T cells. To combat SARS-CoV-2 …
- College: College
Food, Agricultural, and
- Inventors: Gourapura, Renukaradhya; Boley, Patricia "Pat"; Kenney, Scott; Schrock, Jennifer
- Licensing Officer: Dahlman, Jason "Jay"